Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Advances in Respiratory Medicine
MENU
Shortcuts Submit an article Guide for Authors Ahead Of Print Author statement Editorial Policy and Information for Authors Reviewers 2020

open access

Vol 75, No 1 (2007)
Guidelines / Expert consensus
Published online: 2007-04-13
Submitted: 2013-02-22
View PDF (polish) Download PDF file
Get Citation

Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group

Maciej Krzakowski, Tadeusz Orłowski, Kazimierz Roszkowski, Marian Reinfuss, Włodzimierz Olszewski, Rodryg Ramlau, Dariusz Kowalski, Krzysztof Konopa, Jacek Jassem, Renata Jankowska, Jerzy Kozielski, Marek Wojtukiewicz, Kazimierz Drosik, Piotr Koralewski
Pneumonol Alergol Pol 2007;75(1):88-94.

open access

Vol 75, No 1 (2007)
GUIDELINES
Published online: 2007-04-13
Submitted: 2013-02-22

Abstract

Small-cell lung cancer is characterized by an aggressive clinical course with high tendency for early dissemination. At presentation, patients are usually symptomatic and with hilar or mediastinal mass at radiography. Staging should be focused on identifying any evidence of distant spread. Chemotherapy including cisplatin and etoposide is a cornerstone of treatment for all patients. Limited-stage disease should be managed by chemotherapy combined with concurrent chest irradiation. All patients who achieve complete response should be considered for elective cranial irradiation. Surgical treatment may be used in highly selected patients with TNM stage I disease, and surgery should always be combined with chemotherapy. Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivorus should undergo careful monitoring for development of a second primary tumour.

Abstract

Small-cell lung cancer is characterized by an aggressive clinical course with high tendency for early dissemination. At presentation, patients are usually symptomatic and with hilar or mediastinal mass at radiography. Staging should be focused on identifying any evidence of distant spread. Chemotherapy including cisplatin and etoposide is a cornerstone of treatment for all patients. Limited-stage disease should be managed by chemotherapy combined with concurrent chest irradiation. All patients who achieve complete response should be considered for elective cranial irradiation. Surgical treatment may be used in highly selected patients with TNM stage I disease, and surgery should always be combined with chemotherapy. Extensive-stage disease should be managed by multi-agent chemotherapy alone. Long-term survivorus should undergo careful monitoring for development of a second primary tumour.

Full Text:

View PDF (polish) Download PDF file
Get Citation

Keywords

small-cell lung cancer; diagnosis; staging; recommendations; chemotherapy; radiotherapy; surgical treatment

About this article
Title

Small-cell lung cancer diagnostic and therapeutic recommendations of Polish Lung Cancer Group

Journal

Advances in Respiratory Medicine

Issue

Vol 75, No 1 (2007)

Article type

Guidelines / Expert consensus

Pages

88-94

Published online

2007-04-13

Bibliographic record

Pneumonol Alergol Pol 2007;75(1):88-94.

Keywords

small-cell lung cancer
diagnosis
staging
recommendations
chemotherapy
radiotherapy
surgical treatment

Authors

Maciej Krzakowski
Tadeusz Orłowski
Kazimierz Roszkowski
Marian Reinfuss
Włodzimierz Olszewski
Rodryg Ramlau
Dariusz Kowalski
Krzysztof Konopa
Jacek Jassem
Renata Jankowska
Jerzy Kozielski
Marek Wojtukiewicz
Kazimierz Drosik
Piotr Koralewski

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl